Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of locally advanced or metastatic non-small cell lung cancer with activating mutations in the tyrosine kinase domain of the EGFR
Measurable disease according to RECIST
Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Life expectancy greater than or equal to (\>/=) 12 weeks
Adequate hematological, liver and renal function
Participants with asymptomatic and stable cerebral metastases receiving medical treatment
You may not be if
Previous chemotherapy or treatment against EGFR for metastatic disease
Treatment with an investigational agent less than 3 weeks before enrollment
History of neoplasm other than non-small cell lung cancer (except carcinoma in situ of the uterine cervix, basal cell skin carcinoma, or prostate carcinoma)
Participants with symptomatic cerebral metastases
Any significant ophthalmologic abnormality
Unstable systemic disease
Coumarins use
Evidence of any other disease, neurological or metabolic dysfunction, physical examination or laboratory finding contraindicating the use of an investigational drug
Participants with pre-existing parenchymal lung disease such as pulmonary fibrosis, lymphangiosis carcinomatosis
Participants with known infection with human immunodeficiency virus (HIV), Hepatitis B (HBV), Hepatitis C (HCV)
